Tagged Articles

pancreatic problems 5 articles

Diabetes drug Janumet safety label updated

The Food and Drug Administration (FDA) has updated the safety label for the type 2 diabetes drug Janumet XR to inform users that incompletely dissolved tablets may be eliminated in the feces. If this occurs often, patients should tell their doctors to evaluate how whether the drug is properly controlling blood sugar levels. Janumet contains a combination of the widely used metformin and sitagliptin, a medication available as a single ingredient in the brand name drug Januvia. Both Janumet and Januvia are known as dipeptidyl peptidase-4 (DPP-4) inhibitors and are in a relatively new class of medications known as incretin ... Read More

FDA, EMA still investigating pancreatic problems with diabetes drugs Byetta, Januvia

U.S. and European drug regulators have yet to reach a final conclusion about whether a widely prescribed class of type 2 diabetes drugs increases the risk of pancreatic problems. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) launched separate investigations a year ago into the safety of so-called incretin mimetics drugs such as Januvia and Byetta after studies linked the medications to acute pancreatitis and pancreatic cancer. Incretin mimetics, which include GLP-1 receptor agonists and DDP-4 inhibitors, work by increasing the release of insulin after meals and by slowing the absorption of food in the gastrointestinal ... Read More

New type of metformin for type 2 diabetes fares well in clinical trials

Elcelyx Therapeutics, a “virtual” biotech firm, is hoping positive clinical trial results with its type 2 diabetes drug NewMet will secure the product’s sale to a larger drug company. NewMet is a delayed-release version of metformin, a widely prescribed drug to treat type 2 diabetes. Metformin is not recommended for patients with kidney problems because it can cause a life threatening condition called lactic acidosis. NewMet, however, is designed especially for patients with compromised kidney function. Many diabetics with kidney problems cannot eliminate metformin efficiently, which causes excess metformin to build up in the blood, leading to lactic acidosis. NewMet ... Read More

Type 2 diabetes drug Victoza may improve vascular health but poses cancer risk

Victoza, a type 2 diabetes treatment that works to regulate glucose, may improve the condition of arteries and possibly protect against heart attack or stroke, a new report shows. However, that benefit will have to be weighed against the drug’s cancer risks. Victoza, also known as liragliutide, is an injection made by Novo Nordisk to treat high blood sugar in type 2 diabetics. Many people may be familiar with the drug’s former spokesperson, celebrity chef Paula Deen, who after accepting the company’s offer to front their drug, admitted she was diagnosed with type 2 diabetes two years prior. She has ... Read More

Type 2 diabetes drug Bydureon recalled throughout Europe

About 92,000 vials of the type 2 diabetes drug Bydureon are being recalled throughout Europe because some of the vials of the long-acting medication were not fully filled. Bydureon is a weekly injectable version of the drug exenatide. It is the same medication in the type 2 diabetes drug Byetta. The affected drug, jointly marketed by AstraZeneca and Bristol-Myers Squibb Co., was recalled from the Netherlands, Ireland, Sweden, Finland and Spain. No Bydureon vials sold in the United States are affected. Spokesmen for the companies say that injecting under-filled vials should not pose any health concerns to patients. Bydureon has a ... Read More